Indications
Long-term maintenance therapy for bronchial obstruction in patients with chronic obstructive pulmonary disease, relieving symptoms and reducing the number of exacerbations.
Method of administration and dosage
Inhalation.
The drug is a capsule with powder for inhalation, which should only be used for inhalation through the mouth using a special inhalation device (breezhaler), which is included in the kit. Capsules cannot be taken orally. Capsules with powder for inhalation should be stored in a blister and removed from it immediately before use.
The recommended dose of Ultibro® Brizhaler® is 50 mcg + 110 mcg (contents of 1 capsule) 1 time per day. Inhalation of the drug is carried out daily, once a day at the same time. If a dose is missed, it should be inhaled as soon as possible.
The patient should be informed that it is inadmissible to use more than 1 dose of the drug per day.
Before starting to use the drug, the patient should be taught the correct technique for using the inhalation device.
If there is no improvement in respiratory function, you should make sure that the patient is using the drug correctly.
The drug should be inhaled and not swallowed.
Special patient groups
Age over 75 years. No dose adjustment is required in patients over 75 years of age.
Renal impairment. Dose adjustment is not required when using the drug in patients with mild or moderate renal impairment. In patients with severe renal impairment or end-stage CKD requiring hemodialysis, the drug Ultibro® Brizhaler® should only be used if the intended benefit outweighs the potential risk.
Liver dysfunction. Dose adjustment is not required when using the drug in patients with mild to moderate liver dysfunction. The use of the drug in patients with severe liver dysfunction has not been studied.
Instructions for using the inhalation device
Each package of the drug Ultibro® Brizhaler® contains :
– 1 device for inhalation — breezehaler;
– blisters with capsules with powder for inhalation.
